07:00 , Apr 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Fas receptor (CD95) In vitro and mouse studies suggest blocking CD95 signaling could help treat...
08:00 , Jan 14, 2013 |  BioCentury  |  Emerging Company Profile

Oncology Venture: Enrichment tool

Oncology Venture ApS has an exclusive license to a computational method to predict patient response to cancer therapies that could provide an efficient and cost-effective way to repurpose compounds that have failed in prior cancer...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Oncology Venture, Topotarget deal

Newco Oncology Venture debuted and acquired exclusive, worldwide rights from Topotarget to APO010, a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6; FASL). In 2Q13, Oncology Venture...
02:28 , Nov 14, 2012 |  BC Extra  |  Company News

Oncology Venture gains rights to Topotarget's APO010

Newco Oncology Venture ApS (Copenhagen, Denmark) debuted on Tuesday and acquired exclusive, worldwide rights from Topotarget A/S (CSE:TOPO) to APO010, a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6;...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Fas receptor (CD95) A study in mice and in human cell culture suggests that antagonizing...
07:00 , Oct 29, 2009 |  BC Innovations  |  Targets & Mechanisms

New autoimmunity targets

Apoptotic cell clearance has been posited as a potential strategy to help prevent autoimmunity, but so far it has not been clear how to modulate the process. Now, two research groups have described actual targets...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Apoxis, Topotarget deal

TOPO will acquire Apoxis for E14.5 million ($19.4 million) in stock. Apoxis’ shareholders will provide Apoxis with a E4 million ($5.3 million) convertible loan prior to the deal’s close and will be eligible for more...